Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New Phase 3 Data in Relapsed/Refractory Multiple Myeloma (RRMM)
Powerful evidence continues to build for early, accessible immunotherapy in RRMM. This large phase 3 trial (MajesTEC-3) evaluated teclistamab plus daratumumab (Tec-Dara) vs standard-of-care triplets (DPd/DVd) in patients with 1–3 prior lines of therapy.
Key Highlights:
- PFS dramatically improved with Tec-Dara (HR 0.17; P<0.0001)
mPFS not reached vs 18.1 months
36-month PFS: 83.4 percent vs 29.7 percent - Consistent benefit across all subgroups, including elderly, len-refractory, high-risk cytogenetics, high tumor burden, soft-tissue plasmacytomas, and prior anti-CD38 exposure
- Deep, durable responses
≥CR: 81.8 percent vs 32.1 percent
ORR: 89.0 percent vs 75.3 percent
MRD-negativity: 58.4 percent vs 17.1 percent - Overall survival significantly improved (HR 0.46; P<0.0001)
36-month OS: 83.3 percent vs 65.0 percent - >90 percent of Tec-Dara pts alive at 6 months remained alive at 30 months
- Quality-of-life advantage: symptom worsening delayed (NR vs 39.9 months)
- Safety manageable
Infections common but declined over time with Q4W dosing, prophylaxis, and established protocols
CRS mostly grade 1–2; ICANS rare (1.1 percent)
Discontinuation rates low
Takeaway:
Tec-Dara is delivering unprecedented depth and durability of response, highly consistent across risk groups, with a favorable survival profile and manageable safety. These data support Tec-Dara as a new standard of care for RRMM as early as first relapse.”
More posts featuring Yan Leyfman.